Caribou Biosciences Reports Promising Phase 1 CAR-T Therapy Results in Lymphoma and Multiple Myeloma

Caribou Biosciences announced promising clinical trial results for its off-the-shelf CAR-T therapies targeting blood cancers. Their therapy vespa-cel (formerly CB-010) demonstrated an 82% overall response rate, with 64% achieving complete remission in patients with advanced B-cell lymphoma, and 51% remaining progression-free at one year, aligning with outcomes from existing patient-specific CAR-T treatments. Vespa-cel is notable for its PD-1 knockout genome-editing strategy designed to improve efficacy by preventing early CAR-T cell exhaustion, and it holds FDA designations including Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track. Additionally, Caribou is evaluating CB-011, an allogeneic anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma, with initial clinical data shared in ongoing Phase 1 trials. The company plans to present further data and discuss the pivotal Phase 3 trial design for vespa-cel in a webcast scheduled for November 3, 2025. These advancements could expand access to effective cell therapies by offering off-the-shelf options rather than patient-specific treatments, potentially accelerating treatment timelines for blood cancer patients.